Gilbert Wagener

1.5k total citations
18 papers, 739 citations indexed

About

Gilbert Wagener is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Gilbert Wagener has authored 18 papers receiving a total of 739 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Cardiology and Cardiovascular Medicine and 4 papers in Surgery. Recurrent topics in Gilbert Wagener's work include Blood Pressure and Hypertension Studies (7 papers), Diabetes Treatment and Management (6 papers) and Lipoproteins and Cardiovascular Health (4 papers). Gilbert Wagener is often cited by papers focused on Blood Pressure and Hypertension Studies (7 papers), Diabetes Treatment and Management (6 papers) and Lipoproteins and Cardiovascular Health (4 papers). Gilbert Wagener collaborates with scholars based in Germany, Netherlands and Italy. Gilbert Wagener's co-authors include Luís M. Ruilope, Lesley Burgess, Mary P. McGowan, A Castaigne, Jean‐Claude Tardif, Morris J. Brown, Scott Chasan-Taber, Handrean Soran, R Češka and Giuseppe Mancia and has published in prestigious journals such as Journal of the American College of Cardiology, PLoS ONE and Stroke.

In The Last Decade

Gilbert Wagener

18 papers receiving 692 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gilbert Wagener Germany 13 359 284 252 139 87 18 739
E L Bravo United States 17 330 0.9× 239 0.8× 258 1.0× 164 1.2× 57 0.7× 30 733
Tetsuro Yoshida Japan 17 531 1.5× 147 0.5× 136 0.5× 181 1.3× 41 0.5× 41 980
Anders Bröijersén Sweden 15 289 0.8× 212 0.7× 124 0.5× 121 0.9× 45 0.5× 27 719
Paolo Pinna Parpaglia Italy 14 334 0.9× 181 0.6× 311 1.2× 171 1.2× 25 0.3× 27 729
Jaimini Cegla United Kingdom 13 153 0.4× 462 1.6× 302 1.2× 95 0.7× 83 1.0× 41 740
Jean Firth South Africa 13 140 0.4× 526 1.9× 188 0.7× 86 0.6× 138 1.6× 23 670
Kazuaki Uchino Japan 17 467 1.3× 167 0.6× 112 0.4× 176 1.3× 27 0.3× 59 703
Nozomu Inamoto Japan 18 346 1.0× 145 0.5× 236 0.9× 372 2.7× 33 0.4× 21 851
William H. Bestermann United States 9 173 0.5× 146 0.5× 206 0.8× 256 1.8× 30 0.3× 13 574
James W.K. Robertson United Kingdom 7 571 1.6× 88 0.3× 335 1.3× 147 1.1× 73 0.8× 7 847

Countries citing papers authored by Gilbert Wagener

Since Specialization
Citations

This map shows the geographic impact of Gilbert Wagener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gilbert Wagener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gilbert Wagener more than expected).

Fields of papers citing papers by Gilbert Wagener

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gilbert Wagener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gilbert Wagener. The network helps show where Gilbert Wagener may publish in the future.

Co-authorship network of co-authors of Gilbert Wagener

This figure shows the co-authorship network connecting the top 25 collaborators of Gilbert Wagener. A scholar is included among the top collaborators of Gilbert Wagener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gilbert Wagener. Gilbert Wagener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Toledo, Manuel, Christian Brandt, Pier Paolo Quarato, et al.. (2021). Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial. Epilepsy & Behavior. 118. 107897–107897. 15 indexed citations
2.
3.
Li, Zhaoyang, Marjie Hard, Grit Andersen, et al.. (2014). Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects. International Journal of Clinical Pharmacology and Therapeutics. 52(4). 314–320. 5 indexed citations
4.
Visser, Maartje E., Gilbert Wagener, Brenda F. Baker, et al.. (2012). Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. European Heart Journal. 33(9). 1142–1149. 140 indexed citations
5.
McGowan, Mary P., Jean‐Claude Tardif, R Češka, et al.. (2012). Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy. PLoS ONE. 7(11). e49006–e49006. 176 indexed citations
6.
Tardif, Jean‐Claude, Mary P. McGowan, R Češka, et al.. (2011). APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA. Journal of the American College of Cardiology. 57(14). E492–E492. 14 indexed citations
7.
Tardif, Jean‐Claude, R Češka, Lesley Burgess, et al.. (2011). Apolipoprotein B Synthesis Inhibition by Mipomersen Reduces LDL-C When Added to Maximally Tolerated Lipid-Lowering Medication in Patients with Severe Heterozygous Hypercholesterolemia †. Journal of clinical lipidology. 5(3). 219–220. 12 indexed citations
8.
Ruilope, Luís M., Bridget‐Anne Kirwan, Sophie de Brouwer, et al.. (2007). Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. Journal of Hypertension. 25(8). 1711–1718. 19 indexed citations
9.
Wagener, Gilbert. (2007). Calcium Antagonists and Hypertension: Role of co-existent coronary disease, impaired renal function and diabetes. RePub (Erasmus University, Rotterdam). 1 indexed citations
10.
Lubsen, Jacobus, Gilbert Wagener, Bridget‐Anne Kirwan, Sophie de Brouwer, & Philip A. Poole‐Wilson. (2005). Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. Journal of Hypertension. 23(3). 641–648. 85 indexed citations
11.
Leeuw, Peter W. de, Luís M. Ruilope, Christopher R. Palmer, et al.. (2004). Clinical Significance of Renal Function in Hypertensive Patients at High Risk. Archives of Internal Medicine. 164(22). 2459–2459. 73 indexed citations
12.
Bendersky, Mario, et al.. (2004). Effects of the Combination of Low-Dose Nifedipine GITS 20 mg and Losartan 50 mg in Patients with Mild to Moderate Hypertension. Journal of Cardiovascular Pharmacology. 43(2). 300–305. 19 indexed citations
13.
Mancia, Guiseppe, Luís M. Ruilope, C. Palmer, et al.. (2004). Effects of nifedipine GITS and diuretics in isolated systolic hypertension - a subanalysis of the INSIGHT study. Blood Pressure. 13(5). 310–315. 13 indexed citations
14.
Mancia, Giuseppe, Morris J. Brown, A Castaigne, et al.. (2003). Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 41(3). 431–436. 108 indexed citations
15.
Mancia, Giuseppe, Luís M. Ruilope, Morris J. Brown, et al.. (2002). The effect of nifedipine GITS on outcomes in patients with previous myocardial infarction: A subgroup analysis of the INSIGHT study. British Journal of Cardiology. 9(7). 401–405. 4 indexed citations
16.
Fruhstorfer, H. & Gilbert Wagener. (1993). EFFECTS OF INTRADERMAL LIGNOCAINE AND MEPIVACAINE ON HUMAN CUTANEOUS CIRCULATION IN AREAS WITH HISTAMINE-INDUCED NEUROGENIC INFLAMMATION. British Journal of Anaesthesia. 70(2). 167–172. 13 indexed citations
17.
Bielenberg, Gerhard Wilhelm, Gilbert Wagener, & T. Beck. (1992). Infarct reduction by the platelet activating factor antagonist apafant in rats.. Stroke. 23(1). 98–103. 25 indexed citations
18.
Wagener, Gilbert, et al.. (1990). Effects of ipsapirone on spatial and temporal changes in somatosensory evoked potentials after middle cerebral artery occlusion in the rat.. PubMed. 21(12 Suppl). IV167–70. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E L Bravo Breakdown of academic impact, for papers by Tetsuro Yoshida Breakdown of academic impact, for papers by Anders Bröijersén Breakdown of academic impact, for papers by Paolo Pinna Parpaglia Breakdown of academic impact, for papers by Jaimini Cegla Breakdown of academic impact, for papers by Jean Firth Breakdown of academic impact, for papers by Kazuaki Uchino Breakdown of academic impact, for papers by Nozomu Inamoto Breakdown of academic impact, for papers by William H. Bestermann Breakdown of academic impact, for papers by James W.K. Robertson
Rankless by CCL
2026